Hazards of Transfusion

Pediatric Hematology: Third Edition

Volumn , Issue , 2007, Pages 724-744

  Luban, Naomi L C ^a   Wong, Edward C C ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute hemolytic transfusion reactions; Febrile reactions; Massive transfusion; Transfusion hazard; Transfusion related acute lung injury

Indexed keywords

EID: 41149174181     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987001.ch33     Document Type: Chapter

References (167)

1. Angiolillo A, Luban NL. Hemolysis following an out-of-group platelet transfusion in an 8-month-old with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2004; 26: 267-9.
2. Josephson CD, Mullis NC, Van Demark C et al. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A, B: implications for transfusion policy. Transfusion 2004; 44: 805-8.
3. Davenport RD, Streiter RM, Kunkel SL. Red cell ABO incompatibility and production of tumor necrosis factor-alpha. Br J Haematol 1991; 78: 540-4.
4. Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment. Transfusion 1995; 35: 513-20.
5. Silliman CC, Boshkov LK, Mehdizadehkashi Z et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101: 454-62.
6. Bux J, Becker F, Seeger W et al. Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 1996; 93: 707-13.
7. Leach M, Vora AJ, Jones DA et al. Transfusion-related acute lung injury (TRALI) following autologous stem cell transplant for relapsed acute myeloid leukemia: a case report and review of the literature. Transfus Med 1998; 8: 333-7.
8. Wolf CF, Canale VC. Fatal pulmonary hypersensitivity reaction to HL-A incompatible blood transfusion: report of a case and review of the literature. Transfusion 1976; 16: 135-40.
9. Nouraei SM, Wallis JP, Bolton D et al. Management of transfusion-related acute lung injury with extracorporeal cardiopulmonary support in a four-year-old child. Br J Anaesth 2003; 91: 292-4.
10. Yang X, Ahmed S, Chandrasekaran V. Transfusion-related acute lung injury resulting from designated blood transfusion between mother and child: a report of two cases. Am J Clin Pathol 2004; 121: 590-2.
11. Webert KE, Blajchman MA. Transfusion-related acute lung injury. Transfus Med Rev 2003; 17: 252-62.
12. Gilstad CW, Kessler C, Sandler SG. Transfusing patients with anti-immunoglobulin A sub-class antibodies. Vox Sang 2002; 83: 363.
13. Brecher ME (ed.) Technical Manual, 13th edn. Bethesda, MN: American Association of Blood Banks, 2003.
14. King KE, Shirey RS et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004: 44: 25-9.
15. Heddle NM, Klama L, Meyer R, Thoman SK et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39: 231-8.
16. Heddle NM, Blajchman MA, Meyer RM et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556-66.
17. Couban S, Carruthers J, Andreou P et al. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 2002; 42: 753-8.
18. Scanlon JW, Krakaur R. Hyperkalemia following exchange transfusion. J Pediatr 198; 96: 108-19.
19. Brown KA, Bissonnette B, McIntyre B. Hyperkalemia during rapid blood transfusion and hypovolemic cardiac arrest in children. Can J Anaesth 1990; 37: 747-54.
20. Blanchette VS, Grey E, Hardie MJ et al. Hyperkalemia following exchange transfusion: Risk eliminated by washing red cell concentrates. J Pediatr 1993; 123: 285.
21. Beutler E, Meul A, Wood LA. Depletion and regeneration of 2,3-diphosphoglyceric acid in stored red blood cells. Transfusion 1969; 9: 109-15.
22. Boyan CP, Howland WS. Cardiac arrest and temperature of blood bank blood. N Engl J Med 1963; 183: 58-60.
23. Phillips TF, Soulier G, Wilson RF. Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma 1987; 27: 903-10.
24. Blajchman MA. Bacterial contamination of cellular blood components: risks, sources and control. Vox Sang 2004; 87: 98-103.
25. Goldman M, Blajchman M. Bacterial contamination. In: Popovsky M (ed.) Transfusion Reactions. Bethesda, MD: American Association of Blood Banks, 1996, pp. 126-58.
26. Wagner SJ, Moroff G, Katz AJ et al. Comparison of bacteria growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion 1995; 35: 298-302.
27. Kuehnert MJ, Roth VR, Haley R et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 1493-9.
28. Perez P, Salmi LR, Follea G et al. BACTHEM Group; French Haemovigilance Network: Determinants of transfusion-associated bacterial contamination: Results of the French BACTHEM Case-Control Study. Transfusion 2001; 41: 862-72.
29. Yomtovian R, Lazarus HM, Goodnough LT et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33: 902-9.
30. Wagner S. Transfusion-related bacterial sepsis. Curr Opin Hematol 1997; 4: 464-9.
31. Workshop on Bacterial Contamination of Platelets. Bethesda, MD: FDA, Center for Biologics Evaluation and Research, 1999. http://www.fda;gov/cber/minutes/workshop-min.htm.
32. Wagner, SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004; 86: 157-63.
33. Urbaniak SJ, Robertson AE. A successful program for immunizing Rh-negative volunteers for anti-D production using frozen/thawed blood. Transfusion 1981; 21: 64-9.
34. Jakobowicz R, Williams L, Silberman F. Immunization of Rh negative volunteers by repeated injections of very small amounts of Rh positive blood. Vox Sang 1972; 23: 376-81.
35. Issitt PD. Applied Blood Group Serology, 3rd edn. Miami: Montgomery Scientific, 1985, pp. 9-42.
36. Giblett ER. A critique of the theoretical hazard of inter-vs. intra-racial transfusion. Transfusion 1961; 1: 233-8.
37. Floss AM, Strauss RG, Goeken N et al. Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986; 26: 419-22.
38. Ludvigsen CW Jr, Swanson JL, Thompson TR et al. The failure of neonates to form red blood cell alloantibodies in response to multiple transfusions. Am J Clin Pathol 1987; 87: 250-1.
39. Pass MA, Johnson JD, Shulman IA et al. Evaluation of a walking-donor blood transfusion program in an intensive care nursery. J Pediatr 1976; 89: 646-51.
40. Rawls WE, Wong CL, Blajchman M et al. Neonatal cytomegalovirus infections: the relative role of neonatal blood transfusion and maternal exposure. Clin Invest Med 1984; 7: 13-19.
41. Smith MR, Storey CG. Allo-anti-E in an 18-day-old infant [letter]. Transfusion 1984; 24: 540.
42. DePalma L, Criss VR, Roseff SD et al. Presence of the red cell alloantibody anti-E in an 11-week-old infant. Transfusion 1992; 32: 177-9.
43. Nurse GT. Directed donation and the developing world [letter]. Transfusion 1993; 33: 90.
44. DePalma L, Duncan B, Chan MM et al. The neonatal immune response to washed and irradiated red cells: lack of evidence of lymphocyte activation. Transfusion 1991; 31: 737-42.
45. Sarnaik S, Schornack J, Lusher JM. The incidence of development of irregular red cell antibodies in patients with sickle cell anemia. Transfusion 1986; 26: 249-52.
46. Orlina AR, Unger PJ, Koshy M. Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978; 5: 101-6.
47. Rosse WF, Gallagher D, Kinney TR et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990; 76: 1431-7.
48. Vichinsky EP, Earles A, Johnson RP et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-21.
49. Luban NLC. Variability in rates of alloimmunization in different groups of children with sickle cell disease: Effect of ethnic background. Am J Pediatr Hematol Oncol 1989; 11: 314-19.
50. Aygun B, Padmanabhan S, Paley C et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
51. Smith-Whitley K. Alloimmunization in patients with sickle cell disease. In: Herman J and Manno CS (eds) AABB Press, 2002, pp. 249-77.
52. Garratty G, Glynn SA, McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004; 44: 703-6.
53. Ambruso DR, Githens JH, Alcorn R et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987; 27: 94-8.
54. Castellino S, Combs M, Zimmerman S et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999; 104: 189-94.
55. Garratty G. Autoantibodies induced by blood transfusion. Transfusion 2004; 44: 5-9.
56. King KE, Shirey RS, Lankiewicz MW et al. Delayed hemolytic transfusion reactions in sickle cell disease: Simultaneous destruction of recipients' red cells. Transfusion 1997; 37: 376-81.
57. Petz LD, Calhoun L, Shulman IA et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997; 37: 382-92.
58. Sirchia G, Zanella A, Parravicini A et al. Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion 1985; 25: 110-12.
59. Ameen R, Al-Shemmari S, Al-Humood S et al. RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. Transfusion 2003; 43: 1604-10.
60. Spanos Th, Karageorga M, Ladis V et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58: 50-5.
61. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L et al. Alloimmunization to red cell antigens in thalassemia: Comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52: 95-8.
62. Seftel MD, Growe GH, Petraszko T et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333-9.
63. Sirchia G, Rebulla P. Evidence-based medicine: the case for white cell reduction. Transfusion 1997; 37: 543-9.
64. Deeg HJ, Sigaroudinia M. Ultraviolet B-induced loss of HLA class II antigen expression on lymphocytes is dose, time, and locus dependent. Exp Hematol 1990; 18: 916-19.
65. Andreu G, Boccaccio C, Klaren J et al. The role of UV radiation in the prevention of human leukocyte antigen alloimmunization. Transfus Med Rev 1992; 6: 212-24.
66. Blundell EL, Pamphilon DH, Fraser ID et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996; 36: 296-302.
67. Trial to Reduce Alloimmunization to Platelets (TRAP) Study Group. Leukocyte reduction and ultraviolet and irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Eng J Med 1997; 337: 1661-9.
68. Strauss RG. Selection of white cell-reduced blood components for transfusions during early infancy. Transfusion 1993; 33: 352-7.
69. Bedford-Russell AR, Rivers RPA, Davey N. The development of anti-HLA antibodies in multiply transfused preterm infants. Arch Dis Child 1993; 68: 49-51.
70. Skacel PO, Stacey TE, Tidmarsh CEF et al. Maternal alloimmunization to HLA, platelet and granulocyte-specific antigens during pregnancy: its influence on cord blood granulocyte and platelet counts. Br J Haematol 1989; 71: 119-23.
71. Elbert C, Strauss RG, Barrett F et al. Biological mothers may be dangerous blood donors for their neonates. Acta Haematol 1991; 85: 189-91.
72. Dutcher JP, Schiffer CA, Aisner J et al. Long term follow up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981; 58: 1007-11.
73. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987; 70: 1727-9.
74. Schiffer CA, Lichtenfeld JL, Wiernik PH et al. Antibody response in patients with acute nonlymphocytic leukemia. Cancer 1976; 37: 2177-82.
75. Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981; 58: 122-8.
76. Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990; 30: 622-5.
77. Shulman NR, Aster RH, Leitner A et al. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement fixing antibody against a genetically controlled platelet antigen: A proposed mechanism for thrombocytopenia and its relevance in autoimmunity. J Clin Invest 1961; 40: 1597-1620.
78. McFarland JG. Post-transfusion purpura. In: Popovsky MA (ed.) Transfusion Reactions, 2nd edn. Bethesda, MD. 2nd edition: AABB Press, 2001, pp. 187-212.
79. Kickler TS, Ness PM, Herman JH et al. Studies on the pathophysiology of post-transfusion purpura. Blood 1986; 68: 347-50.
80. a and anti-PIA2 platelet antibodies and delayed haemolytic transfusion reaction. Vox Sang 1987; 52: 313-17.
81. Valentin N, Vergracht A, Bignon J et al. HLA-Dw52a is involved in alloimmunization against PL A1 antigen. Hum Immunol 1990; 27: 73-9.
82. Brecher ME, Moore SB, Letendre L. Post-transfusion purpura: the therapeutic value of PlA1-negative platelets. Transfusion 1990; 30: 433-5.
83. Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immuno-competent recipients. Transfus Med Rev 1996; 10: 31-43.
84. Lee TH, Donegan E, Slichter S et al. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 1995; 85: 1207-44.
85. Utter GH, Owings JT, Lee TH. Blood transfusion is associated with donor leukocyte microchimerism in trauma patients. J Trauma 2004; 57: 702-7.
86. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of graft-versus-host disease. Inst J Hematol 2003; 78: 181-7.
87. Rubinstein A, Radl J, Cottier H. Unusual combined immunodeficiency syndrome exhibiting kappa-IgD paraproteinemia, residual gut immunity and graft versus host reaction after plasma infusion. Acta Paediatr Scand 1973; 62: 365-72.
88. Wagner FF, Flegel WA. Transfusion associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995; 35: 284-91.
89. Antin JG, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-8.
90. Reddy P, Ferrara JL. Immunobiology of acute graft vs. host disease. Blood Rev 2003; 17: 187-94.
91. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev 1992; 2: 116-23.
92. Ohto H, Anderson KC. Post-transfusion graft-versus-host disease in Japanese newborns. Transfusion 1996; 36: 117-23.
93. Hathaway WE, Brangle RW, Nelson TL et al. Aplastic anemia and alymphocytosis in an infant with hypogammaglobulinemia: Graft-versus-host reaction? J Pediatr 1966; 68: 713-22.
94. Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000; 40: 1528-40.
95. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315-21.
96. Leitman SF, Tisdale JF, Bolan CD et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003; 43: 1667-71.
97. Shivdasani RA, Haluska FG, Dock NL et al. Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993; 328: 766-70.
98. Ohto H, Yasuda H, Noguchi M et al. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion 1992; 32: 691-3.
99. Kruskall MS, Lee TH, Assmann SF et al. Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001; 98: 272-9.
100. Pelszynski MM, Moroff G, Luban NLC et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683-9.
101. Anand AJ, Dzik WH, Imam A et al. Radiation-induced red cell damage: role of reactive oxygen species. Transfusion 1997; 37: 160-5.
102. Grass JA, Wafa T, Reames A et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-7.
103. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1-7.
104. Fast LD. The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses. Transfusion 2003; 43: 576-83.
105. Luban NLC. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001; 38 (4 suppl. 11): 34-45.
106. Clark DA, Gunby J, Daya S. The use of allogeneic leukocytes or IV IgG for the treatment of patients with recurrent spontaneous abortions. Transfus Med Rev 1997; 11: 85-94.
107. Peters WR, Fry RD, Fleshman JW et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum 1989; 32: 749-53.
108. Williams JG, Hughes LE. Effect of perioperative blood transfusion on recurrence of Crohn's disease (letter). Lancet 1989; 2: 1524.
109. Blajchman MA, Dzik S, Vamvakas EC et al. Clinical and molecular basis of transfusion-induced immunomodulation: Summary of the proceedings of a state-of-the-art conference. L Transfusion Med Rev 2001; 15: 108-35.
110. Vamvakas EC. White blood cell-containing allogeneic blood transfusion, postoperative infection and mortality: A metaanalysis of observational "before-and-after" studies. Vox Sang 2004; 86: 111-19.
111. Puppo F, Ghio M, Contini P et al. Fas, Fas ligand, and transfusion immunomodulation. Transfusion 2001; 41: 416-18.
112. Vamvakas, EC. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175-86.
113. Busch O, Hop W, van Papendrecht M et al. Blood transfusion and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-6.
114. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573-8.
115. Heiss MM, Mempel W, Jauch KW et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342: 1328-33.
116. Jensen LS, Andersen AJ, Christiansen PM et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513-16.
117. Jensen LS, Kissmeyer-Nielson P, Wolff B et al. Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5.
118. van de Watering LM, Hermans J, Houbiers JG et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation 1998; 97: 562-8.
119. Tartter PI, Mohandas K, Azar P et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176: 462-6.
120. Houbiers JG, van de Velde CJ, van de Watering LM et al. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: A prospective study. Transfusion 1997; 37: 126-34.
121. Titlestad IL, Ebbesen LS, Ainsworth AP et al. Leukocyte-depletion of blood components does not significantly reduce the risk of infections complications. Results of a doubleblinded, randomized study. Int J Colorectal Dis 2001; 16: 147-53.
122. Wallis JP, Chapman CE, Orr KE et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42: 1127-34.
123. Busch MP, Lee T-H, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: Implications for transfusion support of infected patients. Blood 1992; 80: 2128-35.
124. Collier AC, Kalish LA, Bush MP et al. Leukocyte-reduced red blood cell transfusion in patients with anemia and human immunodeficiency infection: The Viral Activation Transfusion Study: A randomized controlled trial. JAMA 2001; 285: 1592-601.
125. Asmuth DM, Kalish LA Laycock ME et al. Absence of HBV and HCV, HTLV-I and-II and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infections. Transfusion 2003; 43: 451-8.
126. Williams AE, Thomson RA, Schreiber GB et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997; 277: 967-72.
127. Shimitzu YK, Yoshikura H, Hijikata M et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494-500.
128. Ogata NR, Alter HJ, Miller RH et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 3392-6.
129. Dodd RY, Notari IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
130. Kleinman S, Chan P, Robillard P. Risk associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17: 120-62.
131. Alter M, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 1992; 327: 1899-905.
132. Tong MJ, El-Farra NS, Reikes AR et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
133. Casiraghi MA, De Paschale M, Romano L et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39: 90-6.
134. Strickland DK, Riely CA, Patrick CC et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000; 95: 3065-70.
135. Badizagen K, Jonas M, Ott MJ et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416.
136. Ni Y, Chang M, Lin K et al. Hepatitis C viral infection in thalassemic children: Clinical and molecular studies. Pediatr Res 1996; 39: 323-8.
137. Vogt M, Lang T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.
138. Alter HJ, Nakatsuji Y, Melpolder J et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336: 747-54.
139. Alter HJ. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 1997; 37: 569-72.
140. Stark K, Bienzle U, Hess G et al. Detection of the hepatitis G virus genome among injecting drug users, homosexual and bisexual men, and blood donors. J Infect Dis 1996; 174: 1320-3.
141. Roth W, Waschk D, Marx S et al. Prevalence of hepatitis G virus and its strain variant, the GB agent in blood donations and their transmission to recipients. Transfusion 1997; 37: 651-6.
142. Alter M, Gallagher M, Morris T et al. Acute non A-E hepatitis in the United States and the role of hepatitis G infection. N Engl J Med 1997; 336: 741-6.
143. Fischler B, Lara C, Chen M et al. Genetic evidence for mother-to-infant transmission of hepatitis G virus. J Infect Dis 1997; 176: 281-5.
144. Handa A, Jubran RF, Dickstein B et al. GB virus C/hepatitis G virus infection is frequent in American children and young adults. Clin Infect Dis 2000; 30: 569-71.
145. Neilson J, Harrison P, Milligan DW et al. Hepatitis G virus in long-term survivors of haematological malignancy. Lancet 1996; 347: 1632-3.
146. Kew MC, Kissianides C. HGV: hepatitis G virus or harmless G virus? Lancet 1996; 348 (suppl. II): 10.
147. Kudo T, Morishima T, Tsuzuki et al. Hepatitis G virus in immunosuppressed paediatric allograft recipients. Lancet 1996; 348: 751.
148. Lopez-Alcorocho JM, Millan A, Garcia-Trevijano ER et al. Detection of hepatitis GB virus type C RNA in serum and liver of children with chronic viral hepatitis B and C. Hepatology 1997; 25: 1258-60.
149. Kiem HP, Myerson D, Storb R et al. Prevalence of hepatitis G virus in patients with aplastic anemia. Blood 1997; 90: 1335-6.
150. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289: 959-62.
151. Phelps R, Robbins K, Liberti T et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004; 44: 929-33.
152. Busch MD, Young MJ, Simpson SM et al. Risk of human immunodeficiency virus transmission by blood transfusion prior to implementation of HIV antibody screening in the San Francisco Bay area. Transfusion 1991; 31: 4-11.
153. Kleinman SH, Niland JC, Azen SP et al. Prevalence of antibodies to human immunodeficiency virus type among blood donors prior to screening: the Transfusion Safety Study/NHLBI donor repository. Transfusion 1989: 29: 572-80.
154. Jones DS, Byers RH, Bush TJ et al. Epidemiology of transfusion-associated acquired immunodeficiency syndrome in children in the United States, 1981 through 1989. Pediatrics 1993; 89: 123-7.
155. Lieb LE, Mundy TM, Goldfinger D et al. Unrecognized human immunodeficiency virus type 1 infection in a cohort of transfused neonates: a retrospective investigation. Pediatrics 1995; 95: 717-21.
156. Wayne C, Cornell M, O'Donnell R et al. Seroprevalence of HIV in a transfused pediatric cardiac cohort in a high prevalence area. Transfusion 1993: 33: 544.
157. Lamberson HV, McMillan JA, Weiner LB et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening donors for IgM to CMV. J Infect Dis 1988; 157: 820-3.
158. Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
159. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection [letter]. Blood 1996; 87: 4910.
160. Nichols WG, Price T, Gooley T. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-200.
161. Fraser GA, Walker II, Canadian Blood and Marrow Transplant Group. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004; 10: 287.
162. UK reports potential case of transfusion-transmitted vCJD. AABB Weekly Report 2003; 9(44): 1.
163. McCullough J, Anderson D, Brookie D. Consensus conference on vCJD screening of blood donors: report of the panel. Transfusion 2004; 44: 675-83.
164. Zavizion B, Pereira M, de Melo Jorge M. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004; 44: 731-8.
165. Hsu HY, Ni YH, Chen HL et al. TT virus infection in healthy children, children after blood transfusions, and children with non-A to E hepatitis or other liver diseases in Taiwan. J Med Virol 2003; 69: 66-71.
166. Matsubayashi K, Nagaoka Y, Sakata H et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 2004; 44: 934-40.
167. Petrides M, Aubuchon JP. To transfuse or not transfuse: an assessment of issues and benefits in transfusion therapy 2nd edition. Mintz PD et al. AABB Press 2003, pp. 657-83.